Cyclin-dependent kinase 4/6 inhibitors
Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase.
Cyclin-dependent kinase 4/6 inhibitors are a class of targeted anticancer therapies that block the activity of Cdk4 and CDK6, key regulators of cell-cycle progression from the G1 phase to the S phase. By inhibiting these kinases, the drugs reduce phosphorylation of retinoblastoma pathway components and slow proliferation of tumor cells that depend on cyclin D–Cdk4/6 signaling. In clinical oncology, this mechanism has made Cdk4/6 inhibitors an important component of endocrine-based treatment strategies, especially in hormone receptor-positive, HER2-negative advanced breast cancer.
The best-established clinical role of this drug class is in combination with hormone therapy, where Cdk4/6 inhibitors are used to enhance and prolong disease control. Their use has also prompted investigation into broader biologic effects, including differences in toxicity profiles among agents such as palbociclib and abemaciclib, and potential interactions with immune and inflammatory pathways such as CD274 molecule, the cGAS-STING pathway, and systemic markers like C-reactive protein (CRP). Outside breast cancer, research has explored whether these agents may have activity in other malignancies, although benefits have been more limited in some settings.
Where the papers sit
8 papers from the last 6 months study cyclin-dependent kinase 4/6 inhibitors directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 4 observational · 2 preclinical · 2 unclassified
Themes one subject · 1 new direction
Those 8 are all about one subject.
-
CDK4/6 Treatment Outcomes
Treatment research is broadening beyond response rates toward individualized management of CDK4/6 inhibitor therapy. Biomarkers such as SUV39H2 exon skipping and LINC01871 may clarify resistance or sensitivity, while machine-learning and landmark models aim to predict survival and guide sequencing. Toxicity-driven treatment modification, healthcare costs, and first- versus second-line choices remain central clinical constraints. Immune responses and subtype-specific vulnerabilities suggest potential expansion beyond HR+/HER2-negative breast cancer, but validation across cancers is still needed.
CDK4/6 inhibition can function as an immune-response primer in esophageal squamous cell carcinoma
Palbociclib treatment in treatment-naive esophageal squamous cell carcinoma models showed that CDK4/6 inhibition is not limited to suppressing cell-cycle progression: in delayed responders, it caused DNA-damage accumulation and cGAS-enriched micronuclei, activated interferon-stimulated genes, and increased immune-cell infiltration in vascularized three-dimensional spheroids 42215475May. This introduces an immunomodulatory role for CDK4/6 inhibitors—potentially exposing tumors to immune attack—rather than treating them only as direct antiproliferative agents in the established breast-cancer treatment framework.
Papers
The 8 papers from the last 6 months that study cyclin-dependent kinase 4/6 inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
CDK4/6 Treatment Outcomes (8)
- Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
- Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical drug investigation · 28 Sept 2026 PMID 42806185
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
- LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
- Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
- Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
By study type
Observational studies and case reports (4)
- Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer. Clinical drug investigation · 28 Sept 2026 PMID 42806185
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786218
- Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer. Breast cancer (Tokyo, Japan) · 7 Aug 2026 PMID 42565974
- Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study. Breast cancer research and treatment · 31 Jul 2026 PMID 42536225
Preclinical: animal, cell and lab studies (2)
- Targeting SUV39H2 exon skipping reverses resistance to CDK4/6 inhibitors via transcriptional activation of p21. Science advances · 9 Oct 2026 PMID 42853938
- LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of visualized experiments : JoVE · 9 Sept 2026 PMID 42714000
Unclassified: not yet indexed with MeSH (2)
- Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer. The oncologist · 10 Jun 2026 PMID 42266036
- CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma. Cell death & disease · 29 May 2026 PMID 42215475
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.